Processing

Please wait...

Settings

Settings

Goto Application

1. CN105814028 - 作为免疫调节剂的1,2,4‑*二唑衍生物

Office
China
Application Number 201480057738.X
Application Date 05.09.2014
Publication Number 105814028
Publication Date 16.02.2018
Grant Number 105814028
Grant Date 16.02.2018
Publication Kind B
IPC
C07D 271/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
C07D 285/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
285Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/-C07D283/183
01Five-membered rings
02Thiadiazoles; Hydrogenated thiadiazoles
04not condensed with other rings
081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
A61K 31/4245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4245Oxadiazoles
A61K 31/433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
433Thiadiazoles
CPC
A61K 31/433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
433Thidiazoles
C07D 273/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
273Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
08having two nitrogen atoms and more than one oxygen atom
A61K 31/4245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
4245Oxadiazoles
C07D 271/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
C07D 273/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
273Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
Applicants 奥瑞基尼探索技术有限公司
Inventors 帕塔伊尔·戈文丹·奈尔·萨西库玛
穆拉里哈拉·拉马钱德拉
西塔拉马伊阿·塞提·苏达山·纳里马德帕里
Agents 中科专利商标代理有限责任公司 11021
Priority Data 4011/CHE/2013 06.09.2013 IN
Title
(ZH) 作为免疫调节剂的1,2,4‑*二唑衍生物
Abstract
(ZH) 本发明涉及1,2,4‑二唑和1,2,4‑噻二唑化合物,这些化合物作为能够抑制程序性细胞死亡1(PD1)信号传导通路的治疗剂。本发明还涉及所述治疗剂的衍生物。本发明还包括所述治疗剂和5种衍生物用于经由包括抑制由PD‑1、PD‑L1、或PD‑L2诱导的免疫抑制信号的免疫增强作用治疗病症的用途,以及使用它们的疗法。